Pfizer has gained ... than ever before. The drug is a phosphodiesterase-4 (PDE4) inhibitor targeting an anti-inflammatory mechanism already exploited by treatments for asthma, COPD and psoriasis.

Exclusive: Pfizer explores sale of hospital drugs ... helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.5% premarket. Xanax maker Viatris ...

According to Pfizer, FDA made its decision based on results from a Phase III clinical trial(NCT05842967), MONeT (RSV I M munizati ON Study for Adul T s at Higher Risk of Severe Illness), which looked ...